Codexis, Inc. (NASDAQ:CDXS) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
Results of Operations and Financial Condition
Codexis, Inc. (NASDAQ:CDXS) Files An 8-K Results of Operations and Financial Condition
On August9, 2017, Codexis, Inc. (the “Company”) announced its financial results for the quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
|
Item 2.02. |
Financial Statement and Exhibits |
(d) Exhibits.
|
Exhibit No. |
Exhibit Description |
|
99.1 |
Press release dated August 9, 2017 relating to the financial results for the quarter ended June 30, 2017 |
CODEXIS INC ExhibitEX-99.1 2 a991earningsreleaseq22017.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Codexis Reports Financial Results for the Second Quarter of 2017Product sales more than doubled versus prior-year second quarterAffirms 2017 total revenue guidance; increases full year product sales and gross margin guidanceConference call begins at 4:30 pm Eastern time todayREDWOOD CITY,…To view the full exhibit click here
About Codexis, Inc. (NASDAQ:CDXS)
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.